Compounds > 5-(3-methyl-1-triazeno)imidazole-4-carboxamide
Page last updated: 2024-08-25

5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Central Nervous System Neoplasm

5-(3-methyl-1-triazeno)imidazole-4-carboxamide has been researched along with Central Nervous System Neoplasm in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF1

Trials

1 trial(s) available for 5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Central Nervous System Neoplasm

ArticleYear
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Child; Dacarbazine; Humans; Infant; Metabolic Clearance Rate; Monte Carlo Method; Temozolomide

2005